These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21715210)

  • 21. Component pathogen inactivation: a critical review.
    Prowse CV
    Vox Sang; 2013 Apr; 104(3):183-99. PubMed ID: 23134556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Techniques of preparation and indications of labile blood products].
    Clément S
    Transfus Clin Biol; 2011 Apr; 18(2):250-61. PubMed ID: 21474355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogen inactivation in cellular blood components: clinical trials and implications of introduction to transfusion medicine.
    AuBuchon JP
    Vox Sang; 2002 Aug; 83 Suppl 1():271-5. PubMed ID: 12617151
    [No Abstract]   [Full Text] [Related]  

  • 24. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
    Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
    Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risks and side effects of therapy with plasma and plasma fractions.
    MacLennan S; Barbara JA
    Best Pract Res Clin Haematol; 2006; 19(1):169-89. PubMed ID: 16377549
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Expected limits (and possible consequences) of pathogen inactivation technology].
    Lefrère JJ
    Transfus Clin Biol; 2011 Aug; 18(4):468-71. PubMed ID: 21802331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence and significance of the bacterial contamination of blood components.
    Blajchman MA
    Dev Biol (Basel); 2002; 108():59-67. PubMed ID: 12220143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathogen reduction: state of reflection in Ireland.
    Murphy WG
    Transfus Clin Biol; 2011 Aug; 18(4):488-90. PubMed ID: 21803629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lifestyle changes to prevent and control hypertension: do they work? A summary of the Canadian consensus conference.
    Campbell NR; Burgess E; Taylor G; Wilson E; Cléroux J; Fodor JG; Leiter L; Spence JD
    CMAJ; 1999 May; 160(9):1341-3. PubMed ID: 10333841
    [No Abstract]   [Full Text] [Related]  

  • 30. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain.
    Batlle J; Villar A; Liras A; Alonso C; Altisent C; Brito D; Moreno M; Lucía F; Sedano C; Prieto M; Calvente N; Aznar JA; Jiménez V; Soriano V; Martorell JR; Iruín G; Bergua JM; Aguilar C
    Blood Coagul Fibrinolysis; 2008 Jul; 19(5):333-40. PubMed ID: 18600079
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Indications for labile blood products].
    Jeanne M; Rasonglès P
    Rev Prat; 2001 Jun; 51(12):1318-27. PubMed ID: 11503505
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
    Blajchman MA
    Transfus Clin Biol; 2009 May; 16(2):70-4. PubMed ID: 19427252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Canadian Consensus Conference on Dementia. Summary of the issues and key recommendations.
    Wetmore S; Feightner J; Gass D; Worrall G
    Can Fam Physician; 1999 Sep; 45():2136-40, 2143, 2154-9. PubMed ID: 10509225
    [No Abstract]   [Full Text] [Related]  

  • 34. [Costs of safety of blood and blood products].
    Seifried E; Soedel G
    Zentralbl Chir; 1995; 120(8):584-92. PubMed ID: 7571889
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Residual risks of blood transfusion in Rhode Island.
    Sweeney JD; Kurtis J; Starakiewicz J
    Med Health R I; 2005 Jul; 88(7):224-5, 228-31. PubMed ID: 16184827
    [No Abstract]   [Full Text] [Related]  

  • 36. Approaches to the detection of bacterial contamination in cellular blood products.
    Mitchell KM; Brecher ME
    Transfus Med Rev; 1999 Apr; 13(2):132-44. PubMed ID: 10218237
    [No Abstract]   [Full Text] [Related]  

  • 37. Pathogen inactivation of labile blood products.
    Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components
    Transfus Med; 2001 Jun; 11(3):149-75. PubMed ID: 11422945
    [No Abstract]   [Full Text] [Related]  

  • 38. The Canadian Association of Pediatric Surgeons' position paper on the pediatric surgeon and blood-borne pathogens.
    CAPS Ethics and Legal Committee
    J Pediatr Surg; 2008 May; 43(5):936-7. PubMed ID: 18485970
    [No Abstract]   [Full Text] [Related]  

  • 39. Transfusion-transmitted bacterial infection: risks, sources and interventions.
    Wagner SJ
    Vox Sang; 2004 Apr; 86(3):157-63. PubMed ID: 15078249
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The development of a risk management program in response to the spread of bloodborne pathogen illnesses.
    Murphy D
    J Intraven Nurs; 1995; 18(6 Suppl):S43-7. PubMed ID: 8714931
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.